Clozapine REMS Program Update
Effective February 24, the FDA issued a statement effectively ending the requirements of the Clozapine Risk Evaluation and Mitigation Strategies (REMS) Program. The FDA statement is as follows: February 24, 2025 - Beginning today, FDA does not expect prescribers, pharmacies, and patients to participate in the risk evaluation and mitigation strategies (REMS) program for clozapine or to report results of absolute neutrophil count (ANC) blood tests before pharmacies dispense clozapine.
Read More.....
or....
|